Sunday, Nov. 22, 2026 A Vik Media Group publication
Mongevity Longevity in Motion
Leer en español

Study links a blood marker to early ovarian cancer in women’s cancers research

☕ Includes a question for the family ↓

Breast, ovarian and uterine cancerPart of a story we are following · 11 articles · See every update
Golden sunrise over the Owens Bay Nature Trail on Lake Andes NWR in South Dakota.
Golden sunrise over the Owens Bay Nature Trail on Lake Andes NWR in South Dakota.Photo: USFWS Mountain Prairie / Wikimedia Commons, Public domain

Researchers have found a blood marker that was higher in the earliest stages of ovarian cancer, the ones that are hardest to catch. It is still in the research stage, so nothing changes at your doctor’s office yet. It is not yet known whether it can help find this cancer in everyday care.

In a study of 506 people, a marker called Tu-stroma was clearly higher in blood from women with early-stage ovarian cancer than in women with healthy tissue or harmless growths. It did much better than CA125, the blood marker used today.

How the study worked

Researchers measured Tu-stroma in blood samples from 506 people. Some had healthy tissue, some had benign (not cancer) growths, and some had a very early change called STIC or ovarian cancer at stages I through IV. It was a case-control study, which means it compared blood from people who already had a known diagnosis. It was published in Nature Medicine on November 10, 2026. The next step is to try the test in people followed forward in real-world care.

What is Tu-stroma?

Tu-stroma is a small piece of genetic material, a type of RNA. Tumor cells release it inside tiny bubbles called extracellular vesicles, and these travel through the blood. Think of them as little sealed envelopes that tumor cells send out. The test looks for this particular message in a blood sample.

What they found

The cancer in this study is called high-grade serous carcinoma. It is the most common type of epithelial ovarian cancer and the leading cause of death from ovarian cancer. It usually starts as a tiny change in the fallopian tube called STIC. Today, STIC can usually only be found by examining tissue after surgery.

Tu-stroma levels were higher in the 43 people with STIC and the 232 people with high-grade serous cancer. The comparison groups were 143 people with healthy tissue and 88 with benign growths. The same pattern showed up in premenopausal women.

The researchers also measured how well each test tells the groups apart, using a score called AUC, where a higher number means better separation. Tu-stroma scored 0.99 for telling STIC apart from healthy tissue. CA125 scored 0.59, barely better than a coin flip. For benign growths, Tu-stroma scored 0.99 and CA125 only 0.31.

For established cancer, both tests did well, but Tu-stroma still came out ahead. It scored 0.99 against 0.96 for CA125 when comparing cancer to healthy tissue. Against benign growths, it scored 0.98 against 0.84.

The marker also did not rise across the board. It showed no systematic increase in 116 people with inflammatory or normal body conditions, or in 160 people with cancers outside the ovary. Both groups were compared with 100 healthy people. That suggests the signal is specific to this disease.

What you can do today

This test is not available at the doctor’s office or the pharmacy, and current advice does not change. The best step you can take now is to keep up with the regular checkups and well-woman visits your doctor already recommends. Then you will be ready to talk about new tests when they reach clinics.

For clinicians and researchers

Design: Case-control study of serum extracellular vesicle Tu-stroma, a long noncoding RNA, in 506 individuals with histologically normal adnexa, benign-adnexal lesions, isolated STIC and HGSC (FIGO stages I-IV). Groups: controls n = 143, benign n = 88, STIC n = 43, HGSC n = 232.

Main result: Tu-stroma discriminated STIC from controls with AUC = 0.99 versus 0.59 for CA125 (P < 0.001), and HGSC from controls with AUC = 0.99 versus 0.96 (P = 0.001). Tu-stroma ΔCT values were elevated in STIC and HGSC versus controls and benign lesions.

Main limitation: Case-control design with defined groups, not consecutively enrolled real-world cohorts, so diagnostic performance and predictive values (partly modeled) may not carry over to intended-use populations.

Open question: Prospective evaluation in consecutively enrolled real-world cohorts is required to validate diagnostic performance, predictive value and clinical utility.

Talk about it at home

Some cells in our body send out tiny bubbles that float along in the blood, a bit like sealed envelopes carrying little messages. In this study, scientists collected blood from many women, some healthy and some with different kinds of growths, and searched for one special message inside those envelopes. Then they compared the groups to see whether the message showed up more in some than in others.

Question for the table

Try a mystery envelope game with scrap paper. Write a short message on some slips, leave other slips blank, seal them all in plain envelopes and mix them up. Take turns holding the envelopes up to a sunny window to guess which ones hold a message, then open them and see how good your guesses were. Why might a scientist want to check a lot of envelopes before trusting a guess?

Keep exploring

Copies this article and its questions so you can paste them into ChatGPT, Claude, Gemini or the AI you use, and keep the conversation going.

Got a question? Ask us ›

Get the best of longevity science by emailThe most useful new studies, in plain language and with the source. Free.

We'll email you once to confirm. Occasional messages from our sponsors, clearly labeled. Unsubscribe anytime. We never ask for health data.
Cite this article
AMA
Mongevity Desk. Study links a blood marker to early ovarian cancer in women’s cancers research. Mongevity. Published November 22, 2026. Accessed November 22, 2026. https://mongevity.science/cancer/2026/11/blood-test-spots-early-ovarian-cancer/
Vancouver
Mongevity Desk. Study links a blood marker to early ovarian cancer in women’s cancers research [Internet]. Mongevity; 2026 Nov 22 cited 2026 Nov 22]. Available from: https://mongevity.science/cancer/2026/11/blood-test-spots-early-ovarian-cancer/
APA
Mongevity Desk. (2026, November 22). Study links a blood marker to early ovarian cancer in women’s cancers research. Mongevity. https://mongevity.science/cancer/2026/11/blood-test-spots-early-ovarian-cancer/
For your website
<a href="https://mongevity.science/cancer/2026/11/blood-test-spots-early-ovarian-cancer/">Study links a blood marker to early ovarian cancer in women’s cancers research</a>

Free to share or quote with credit and a link.

Questions and answers

Can I get this ovarian cancer blood test now?
No. The Tu-stroma test is still in research. It needs to be tried in real-world groups of patients before it can be used in clinics.
What is CA125?
CA125 is the blood marker doctors use today in ovarian cancer care. In this study, Tu-stroma told early disease apart from healthy tissue much better than CA125 did.
What kind of ovarian cancer did the study look at?
High-grade serous carcinoma, the most common type of epithelial ovarian cancer. The study also looked at STIC, a very early change in the fallopian tube that comes before it.
Did the marker rise in other conditions?
The study found no systematic rise in inflammatory or normal body conditions, or in cancers outside the ovary. That points to a signal specific to this disease.

Sources

  1. Nat Med: Blood-based RNA biomarker for the early detection of ovarian cancer (PMID 43009642 · DOI 10.1038/s41591-026-04732-9) · 2026-11-22

More on this story

Report an error